首页> 外文期刊>Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology >A phase I/II study piloting accelerated partial breast irradiation using CT-guided intensity modulated radiation therapy in the prone position
【24h】

A phase I/II study piloting accelerated partial breast irradiation using CT-guided intensity modulated radiation therapy in the prone position

机译:I / II期研究在俯卧位使用CT引导的强度调制放射治疗引导加速的局部乳房照射

获取原文
获取原文并翻译 | 示例
           

摘要

Background and purpose External beam accelerated partial breast irradiation (EB-aPBI) is noninvasive with broader potential applicability than aPBI using brachytherapy. However, it has inherent challenges in daily reproducibility. Image-guide radiotherapy (IGRT) can improve daily reproducibility, allowing smaller treatment margins. Our institution proposed IG-IMRT in the prone position to evaluate dose homogeneity, conformality, normal tissue avoidance, and reliable targeting for EB-aPBI. We report preliminary results and toxicity from a phase I/II study evaluating the feasibility of EB-aPBI in the prone position using IG-IMRT. Materials and methods Twenty post-menopausal women with node-negative breast cancer, excised tumors <3.0 cm, negative sentinel lymph node biopsy, and surgical clips demarcating the lumpectomy cavity underwent prone EB-aPBI using IG-IMRT on an IRB-approved phase I/II study. All patients underwent CT planning in the prone position. The lumpectomy cavity PTV represented a 2.0 cm expansion. 38.5 Gy was delivered in 10 fractions over 5 days, such that 95% of the prescribed dose covered >99% of the PTV. Dose constraints for the whole breast, lungs and heart were met. Results The median patient age was 61.5. Mean tumor size was 1.0 cm. 35% of patients had DCIS. Median PTV was 243 cc (108-530) and median breast reference volume was 1698 cc (647-3627). Average daily shifts for IGRT were (0.6, -4.6, 1.7 mm) with standard deviations of (6.3, 6.5, 6.4 mm). Acute toxicity was G1 erythema in 80%, and G2 erythema, G2 fatigue, and G2 breast pain each occurred in 1 patient. With a median follow-up of 18.9 months (12-35), 40% of patients have G1 fibrosis and 30% have G1 hyperpigmentation. 95% of patients have good to excellent cosmesis. There have been no recurrences. Conclusions These data demonstrate that EB-aPBI in the prone position using IG-IMRT is well tolerated, yields good dosimetric conformality, and results in promising early toxicity profiles.
机译:背景与目的外照射加速的局部乳房照射(EB-aPBI)是非侵入性的,比使用近距离放射治疗的aPBI具有更大的潜在适用性。但是,它在日常重现性方面存在固有的挑战。影像引导放疗(IGRT)可以提高每日重现性,从而缩小治疗范围。我们的机构提出了俯卧位IG-IMRT,以评估剂量均一性,保形性,避免正常组织以及对EB-aPBI的可靠靶向。我们报告了I / II期研究的初步结果和毒性,该研究评估了使用IG-IMRT俯卧位EB-aPBI的可行性。材料和方法二十名绝经后乳腺癌,阴性肿瘤,<3.0 cm切除的肿瘤,前哨淋巴结活检阴性的妇女,以及在IRB批准的I期阶段使用IG-IMRT划定的肿块切除腔的手术夹,均易行EB-aPBI / II研究。所有患者均在俯卧位进行CT计划。肿块切除术腔PTV代表2.0 cm的扩张。 38.5 Gy在5天内分10次递送,因此95%的处方剂量覆盖了99%以上的PTV。满足了整个乳房,肺和心脏的剂量限制。结果患者平均年龄为61.5岁。平均肿瘤大小为1.0厘米。 35%的患者患有DCIS。 PTV中位数为243 cc(108-530),乳腺参考量中位数为1698 cc(647-3627)。 IGRT的平均每日班次为(0.6,-4.6、1.7毫米),标准偏差为(6.3、6.5、6.4毫米)。急性毒性为80%的G1红斑,其中1例患者分别发生G2红斑,G2疲劳和G2乳房疼痛。中位随访18.9个月(12-35),40%的患者患有G1纤维化,30%的患者患有G1色素沉着。 95%的患者具有良好的美容效果。没有重复发生。结论这些数据表明,使用IG-IMRT俯卧位的EB-aPBI具有良好的耐受性,产生了良好的剂量学适形性,并产生了可观的早期毒性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号